ALTERITY THERAPEUTICS LIMITED - AMERICAN DEPOSITAR

Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference

12 Nov 2025 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System

10 Nov 2025 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report

31 Oct 2025 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

09 Oct 2025 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders

02 Oct 2025 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting

15 Sep 2025 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

08 Sep 2025 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Present at the Biotech Showcase

02 Sep 2025 07:25:00 By Nasdaq GlobeNewswire

Appendix 4C – Q4 FY25 Quarterly Cash Flow Report

30 Jul 2025 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

28 Jul 2025 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

24 Jul 2025 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Provide Corporate Update in Fireside Chat

23 Jun 2025 07:25:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Prominently Featured at the International MSA Congress

12 May 2025 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

07 May 2025 08:16:45 By Nasdaq GlobeNewswire

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

05 May 2025 07:35:00 By Nasdaq GlobeNewswire

Appendix 4C – Q3 FY25 Quarterly Cash Flow Report

30 Apr 2025 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium

28 Apr 2025 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

10 Apr 2025 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting

03 Apr 2025 07:35:00 By Nasdaq GlobeNewswire

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

27 Mar 2025 07:25:00 By Nasdaq GlobeNewswire